Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;60(1):100-102.
doi: 10.1038/s41409-024-02451-8. Epub 2024 Oct 25.

Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT

Piera Angelillo #  1 , Ana Alarcon Tomas #  2 , Edoardo Campodonico #  1 , Urban Novak  3 , Ludovic Gabellier  4 , Igor Wolfgang Blau  5 , Mi Kwon  6   7 , Ron Ram  8 , Edouard Forcade  9 , Caroline Besley  10 , Vladan Vucinic  11 , Nicolaus Kröger  12 , Lucía López Corral  13 , Jan Vydra  14 , Silvia Ferrari  15 , Bastian von Tresckow  16 , Marie Therese Rubio  17 , Rafael Hernani  18 , Simona Sica  19 , Friedrich Stölzel  20 , Montserrat Rovira  21 , Eva Wagner-Drouet  22 , Jose Antonio Pérez-Simón  23 , Cristina Castilla-Llorente  24 , Andres J M Ferreri  1 , Jorinde D Hoogenboom  25 , Isabel Sanchez Ortega  26 , Florent Malard  27 , Jürgen Kuball  28 , Annalisa Ruggeri  29
Affiliations

Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT

Piera Angelillo et al. Bone Marrow Transplant. 2025 Jan.
No abstract available

PubMed Disclaimer

References

    1. June CH, Sadelain M. Chimeric Antigen Receptor Therapy | Enhanced Reader. N Engl J Med Rev. 2018;379:64–73. - DOI
    1. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, Mcguirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380:45–56.
    1. Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531–44. - DOI - PubMed - PMC
    1. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382:1331–42. - DOI - PubMed - PMC
    1. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52. - DOI - PubMed

LinkOut - more resources